UNIVERSITY OF SOUTH FLORIDA

Tampa General Hospital and USF Health announce a $162M investment to strengthen their affiliation, focusing on talent, GME programs, academics, and research to enhance health care quality and economic growth in Florida.

Tampa General Hospital and USF Health strengthen their partnership with a $162M investment by 2025, aiming to enhance academic medicine, research, and patient care. This collaboration focuses on recruiting top talent, advancing research, and expanding the health care workforce, setting a new standard in health care delivery and innovation.

Tampa General Hospital and USF Health announce a $162M investment to strengthen their affiliation, focusing on talent recruitment, GME programs, academics, and research. This collaboration aims to enhance health care quality, expand the workforce, and advance research, benefiting patients and the community.

Tampa General Hospital and USF Health announce a $162M investment to strengthen their affiliation, aiming to enhance academic medicine, research, and patient care. This historic agreement focuses on recruiting top talent, advancing research, and expanding the health care workforce, reinforcing their commitment to transforming health care in Florida and beyond.

The FDA approved ARS Pharmaceuticals' needle-free epinephrine nasal spray, marking a significant advancement in treating severe allergic reactions. This innovation offers an alternative to autoinjectors like EpiPen, addressing injection fears. Priced at $199 for two doses, with a co-pay savings program, it aims to improve treatment accessibility and outcomes.

FDA approves neffy (epinephrine nasal spray) 2 mg for Type I Allergic Reactions, including anaphylaxis, in adults and children ≥30 kg, marking the first needle-free epinephrine treatment innovation in over 35 years.

neffy, the first needle-free epinephrine nasal spray for severe allergic reactions, including anaphylaxis, approved by FDA for adults and children ≥30 kg. Offers a new, easy-to-use alternative to injections, aiming to improve treatment accessibility and reduce anxiety. Expected to be available in the U.S. within eight weeks post-approval.

FDA approves Crexont, an extended-release capsule of carbidopa and levodopa for Parkinson's disease treatment, offering more 'Good On' time with less frequent dosing and a safety profile consistent with IR CD/LD.

The Penn State College of Medicine updated trustees on its AI strategies, focusing on enhancing health outcomes, scientific discovery, operational efficiencies, and administrative tasks. With pilot funding in 2023, faculty are advancing AI research, including diagnosing autoimmune diseases early, predicting stroke recurrence, and identifying novel therapeutics, in collaboration with Penn State Health and external partners.

Tampa General Hospital and the University of South Florida are advancing their enhanced affiliation, now named University of South Florida Tampa General Physicians, targeting an October 2021 launch. This collaboration unites over 800 healthcare providers under one management, aiming to deliver world-class care and strengthen the region's academic medical center.